Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 5, 2025
Product Development
Biotechs make inroads to precision medicine, solving long-standing problems
70% of new precision medicines approved by FDA in past three years were not sponsored by major pharmas
BioCentury | Sep 18, 2024
Product Development
View from ESMO: iTeos data keep TIGIT alive, for now
Plus readouts from Genmab, AstraZeneca, Merck, Astellas and more
BioCentury | Sep 14, 2024
Product Development
Rybrevant shows colorectal cancer promise in latest bispecifics win
J&J to bring Rybrevant into two Phase III colorectal cancer studies based on Phase II data
BioCentury | Jul 27, 2024
Data Byte
Junshi’s PD-1 among seven new products recommended by EMA’s CHMP
Plus: Astellas’ Vyloy on track to become EU’s first CLDN18.2 therapy, and 11 products likely headed for label expansions
BioCentury | Jun 27, 2024
Product Development
Solving for the medical and business case in pediatric cancer — Day One
CEO Jeremy Bender on building a strategy for pediatric cancer therapies that serves both patients and investors
BioCentury | May 2, 2024
Data Byte
FDA approved five NMEs in April
Day One, X4 and ImmunityBio each received their first drug approvals
BioCentury | Apr 25, 2024
Regulation
FDA’s Ojemda approval marks Day One’s transition to commercial company
No black box warning and a broad label for the pediatric brain cancer therapy
BioCentury | Mar 8, 2024
Product Development
Pfizer blends modality tools in new vision for oncology unit
Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen
BioCentury | Feb 17, 2024
Regulation
With eyes on manufacturing, Iovance’s TIL therapy reaches long-awaited, world-first approval
Therapy will be made at the biotech’s Philadelphia facility and a nearby CDMO, with plans to serve ‘up to several thousand patients annually’
BioCentury | Oct 30, 2023
Regulation
As priority review starts, Day One preps for shift to commercial phase
Five-year-old biotech receives April PDUFA date for pan-RAF inhibitor to treat slow-moving pediatric brain cancer
Items per page:
1 - 10 of 737